- Home
- RDI vs OCX Comparison
RDI vs OCX Comparison
Compare RDI & OCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- OCX
- Stock Information
- Founded
- RDI 1937
- OCX 2009
- Country
- RDI United States
- OCX United States
- Employees
- RDI N/A
- OCX N/A
- Industry
- RDI Movies/Entertainment
- OCX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- RDI Consumer Discretionary
- OCX Health Care
- Exchange
- RDI Nasdaq
- OCX Nasdaq
- Market Cap
- RDI 32.3M
- OCX 38.7M
- IPO Year
- RDI N/A
- OCX N/A
- Fundamental
- Price
- RDI $1.30
- OCX $2.23
- Analyst Decision
- RDI Hold
- OCX Buy
- Analyst Count
- RDI 1
- OCX 3
- Target Price
- RDI $2.40
- OCX $4.42
- AVG Volume (30 Days)
- RDI 63.7K
- OCX 123.4K
- Earning Date
- RDI 11-14-2024
- OCX 11-12-2024
- Dividend Yield
- RDI N/A
- OCX N/A
- EPS Growth
- RDI N/A
- OCX N/A
- EPS
- RDI N/A
- OCX N/A
- Revenue
- RDI $197,270,000.00
- OCX $709,000.00
- Revenue This Year
- RDI N/A
- OCX N/A
- Revenue Next Year
- RDI $14.40
- OCX $106.34
- P/E Ratio
- RDI N/A
- OCX N/A
- Revenue Growth
- RDI N/A
- OCX N/A
- 52 Week Low
- RDI $1.22
- OCX $1.98
- 52 Week High
- RDI $2.15
- OCX $3.82
- Technical
- Relative Strength Index (RSI)
- RDI 36.63
- OCX 30.62
- Support Level
- RDI $1.45
- OCX $2.18
- Resistance Level
- RDI $1.59
- OCX $2.36
- Average True Range (ATR)
- RDI 0.09
- OCX 0.15
- MACD
- RDI -0.03
- OCX -0.01
- Stochastic Oscillator
- RDI 2.63
- OCX 41.07
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.
About OCX Oncocyte Corporation
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.